Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Gilead Sciences, Inc.NASDAQ: GILD

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 79.8%

Gross margin was 79.8% in Q2 FY2026, up 1.0 pp from a year earlier. On a trailing-twelve-month basis it was 79.6%, up 1.1 pp year over year. Over 3 fiscal years it narrowed by 0.4 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
79.8%+0.5 pp QoQ
Last fiscal yearDec 2025
78.8%+0.6 pp YoY
LTMJun 2026
79.6%+1.1 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.0 pp——
1 year+0.6 pp——
3 years-0.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
78.8%
Year-over-year change
+0.6pp

Gross Margin vs competitors

How GILD compares with its peers on the latest reported figures

  • GILD's LTM Jun 2026 gross margin of 79.6% is the 3rd highest of the 10 companies compared; the peer median is 74.4%.
  • Its year-over-year change of +1.1 pp is the 5th highest of 10, against a peer median of +0.8 pp.
  • Over three fiscal years its change of -0.4 pp compares with a peer median of +1.7 pp.
GILD Competitors Peer median
Gross Margin for GILD and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
GILDGilead Sciences, Inc.LTM Jun 202679.6% +1.1 pp-0.4 pp
ABBVAbbVie Inc.LTM Sep 202676.3% +6.5 pp+0.2 pp
MRKMerck & Co., Inc.LTM Jun 202675.4% -0.1 pp+1.3 pp
NVSNovartis AGLTM Jun 202674.4% -1.8 pp+1.7 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
SNYSanofiLTM Jun 202673.0% +1.4 pp+1.4 pp
GSKGSK plcLTM Jun 202672.7% +1.4 pp+5.0 pp
JNJJohnson & JohnsonLTM Sep 202668.8% +0.7 pp-1.4 pp
Peer median (excluding GILD) 74.4%+0.8 pp+1.7 pp

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.